相关实验视频

Updated: May 6, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

通过对综合临床数据集的分析,完善DDX41变异的分类

Ing Soo Tiong^1,2,3, Sally Hunter^4,5, Yamuna Kankanige^4,6,5

¹Department of Pathology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia. ing-soo.tiong@petermac.org.

|February 17, 2026

概括

有害的DDX41变种强烈倾向于使个体患有骨髓质疏松性瘤和急性骨髓性白血病 (MDS/AML). 这项研究通过使用大型数据集和新的计算模型来完善变异分类准则.

科学领域:

遗传学是一个遗传学.
在瘤学瘤学.
生物信息学是一种生物信息学.

背景情况:

生殖系DDX41变种是遗传性MDS/AML的主要原因.
变种分类的挑战包括晚发病,不完全透和创始人效应.
对于DDX41变种的致病性缺乏标准化指南.

研究的目的:

为DDX41变种分类制定和完善ACMG/AMP标准.
为了利用DDX41变异的大量聚合合成队列 (ASC).
为DDX41特定的策划指南创建一个证据框架.

主要方法:

从35项研究中汇集了1796个生殖系和体质DDX41变体的合成队列 (ASC).
进行了与祖先匹配的准病例控制研究.
开发了一个贝叶斯的多项模型,整合了生殖系-体的关联.
比较计算预测工具,包括AlphaMissense和REVEL.

主要成果:

确定的有害生殖系DDX41变种在MDS/AML中最为普遍.
在代表性不足的群体中确定了变体的高估概率比率.
贝叶斯模型有效地更新了基于体格模式的致病率.
与REVEL相比,AlphaMissense表现出更高的灵敏度.

结论:

这项研究为DDX41变种的分类提供了强有力的证据框架.
开发了一个在线工具,用于一致应用精细的ACMG/AMP标准.
这些发现将为开发用于临床实践的特定DDX41治疗指南提供信息.

更多相关视频

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

相关概念视频

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...